noom glp 1 reviews consumer reports Launches GLP-1 Microdosing for Longevity Noom's GLP-1 Companion Receives Major

Description

2,3 Against this backdrop, oral GLP-1 receptor agonists are emerging as an increasingly important area of focus, as companies look to extend growth beyond injectables and broaden access to obesity care

Common side effects Nausea, especially in the first weeks and after a dose increase Mild constipation or diarrhea Reduced appetite and early fullness Occasional reflux and fatigue in the first weeks Most of these are dose-dependent and improve when we slow the titration pace or adjust how you eat

Aside from the advantage of having higher appeal to people who are squeamish with needles, oral formulations remove the need for cold chain storage for injectable forms of GLP1R/GIPR/GR agonists , which otherwise must be stored at cold temperatures if not provided in a dry (Tablet/pill) form

Some employers have begun to include obesity medications as part of wellness initiatives, recognizing their potential to reduce long-term healthcare costs